|1.||Dai, De-Zai: 2 articles (01/2010 - 04/2007)|
|2.||Dai, Yin: 2 articles (01/2010 - 04/2007)|
|3.||Hamed, Khan Hussien: 1 article (01/2010)|
|4.||Yu, Feng: 1 article (01/2010)|
|5.||Hu, Chen: 1 article (01/2010)|
|6.||Ji, Min: 1 article (04/2007)|
|7.||Huang, Zhi-Jiang: 1 article (04/2007)|
|8.||Li, Na: 1 article (04/2007)|
|9.||Na, Tao: 1 article (04/2007)|
01/01/2010 - "CPU228 was more effective than dofetilide in attenuating heart failure by normalizing isoproterenol-induced changes, including downregulation of FKBP12.6, upregulation of NADPH oxidase and PKC epsilon hyperphosphorylation in vivo and in vitro."
01/01/2010 - "The aim of this study was to determine if CPU228, a derivative of dofetilide, is more effective than dofetilide in attenuating isoproterenol-induced heart failure by recovering downregulated FK506 binding protein (FKBP12.6), and suppressing oxidative stress, upregulated NADPH oxidase and protein kinase C epsilon (PKC epsilon) hyperphosphorylation in the myocardium. "
|2.||Torsades de Pointes (Torsade de Pointes)
|2.||Protein Kinase C-epsilon
|3.||Tacrolimus Binding Proteins (FKBP)
|4.||NADPH Oxidase (NAD(P)H oxidase)
|6.||tacrolimus binding protein 1B